Skinvisible Reiterates Going Concern Warning as Cash Dwindles to $3,959
SKVI has more than doubled off its 52-week low of $0.055.
Summary
Skinvisible's Q2 2026 filing shows a company on the brink: $3,959 in cash, a $5.5 million working capital deficit, defaulted debt, and a reiterated going concern warning.
Key Events · Earnings and Guidance · SKVI
-
Going Concern Warning Reiterated
Management states substantial doubt about the company's ability to continue as a going concern within one year, citing a $522,717 net loss for the six months ended June 30, 2026 and cumulative losses of $41.5 million.
-
Cash Position Nearly Exhausted
Cash on hand is $3,959 as of June 30, 2026, down from $2,620 at year-end 2025. The company has no financing cash inflows in the first half of 2026.
-
Working Capital Deficit Widens
Working capital deficit increased to $5,503,128 from $4,990,414 at December 31, 2025, driven by rising accounts payable and accrued interest.
-
Debt Defaults Disclosed
A $352,075 convertible note (due 2024) and a $10,000 promissory note (due February 2026) are both in default as of June 30, 2026.
Analysis · SKVI · Life Sciences
Skinvisible's Q2 2026 report confirms the company is in critical financial distress. Cash on hand is just $3,959, while current liabilities exceed $5.5 million. The working capital deficit widened by over $500,000 in six months, and the company has two debt instruments in default. Management reiterates substantial doubt about the company's ability to continue as a going concern. The report also discloses unremediated material weaknesses in internal controls, adding governance risk to the financial distress. With 82.98 million shares potentially issuable under convertible notes and warrants, any future financing would be massively dilutive to the current 5.4 million shares outstanding.
At the time of this filing, SKVI was trading at $0.18 on OTC in the Life Sciences sector, with a market capitalization of approximately $972.7K. The 52-week trading range was $0.06 to $0.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.